Psychosis News and Research

RSS

Psychosis means abnormal condition of the mind, and is a generic psychiatric term for a mental state often described as involving a "loss of contact with reality". People suffering from psychosis are said to be ''psychotic.''

New study reveals effect of cannabis potency on brain structure

Smoking high potency 'skunk-like' cannabis can damage a crucial part of the brain responsible for communication between the two brain hemispheres, according to a new study by scientists from King's College London and Sapienza University of Rome.

27 Nov 2015

UNC study reveals how specific schizophrenia symptoms linked to distinct brain circuits

Schizophrenia, a severe mental disorder affecting about one in 100 people, is notoriously difficult to diagnose and treat, in large part because it manifests differently in different people. A new study published today in Molecular Neuropsychiatry helps explain why.

25 Nov 2015

Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo.

24 Nov 2015

People with psychosis and addiction disorder may respond better to disorder-specific treatment

People with psychosis often develop an addiction disorder: almost one in two patients with schizophrenia are affected once during their lifetime. Patients with a dual diagnosis mostly have a poorer prognosis, and their disorder often becomes chronic.

31 Oct 2015

Team-based, coordinated specialty care approach produces better outcomes for people with first episode psychosis

New research shows that treating people with first episode psychosis with a team-based, coordinated specialty care approach produces better clinical and functional outcomes than typical community care. Investigators also found that treatment is most effective for people who receive care soon after psychotic symptoms begin.

20 Oct 2015

Long-term lithium exposure does not increase renal dysfunction risk

Stable lithium maintenance therapy does not increase the risk of renal dysfunction in patients with bipolar affective disorder, findings from a population-based study suggest.

14 Oct 2015

New analysis finds illogical thoughts as most predictive of schizophrenia risk

Despite decades of study, schizophrenia has remained stubbornly difficult to diagnose in its earliest stage - between the appearance of symptoms and the development of the disorder. Now, a new analysis led by researchers at the UNC School of Medicine and the Renaissance Computing Institute identified illogical thoughts as most predictive of schizophrenia risk.

9 Oct 2015

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks.

9 Oct 2015

Vraylar (cariprazine) capsules now approved by FDA to treat schizophrenia, bipolar disorder in adults

The U.S. Food and Drug Administration today approved Vraylar (cariprazine) capsules to treat schizophrenia and bipolar disorder in adults.

9 Oct 2015

Brain & Behavior Research Foundation to honor nine scientists with Outstanding Achievement Prizes

The Brain & Behavior Research Foundation will honor nine scientists with its 2015 Outstanding Achievement Prizes for their work in schizophrenia, mood disorders, child and adolescent psychiatry, and cognitive neuroscience.

9 Oct 2015

Minor hallucinations may predate Parkinson motor symptoms

About four in 10 patients with untreated Parkinson’s disease experience minor hallucinations, research shows.

8 Oct 2015

Study shows antipsychotic medication increases death risk in patients with Parkinson's disease psychosis

Antipsychotic drugs may increase the risk of death in people with Parkinson's disease psychosis (PDP), according to a new study led by researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London.

1 Oct 2015

Mylan releases generic version of Invega in the U.S.

Mylan N.V. today announced the U.S. launch of Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg and 9 mg, the generic version of Janssen's Invega.

28 Sep 2015

Reduced conflict-related brain activity linked to higher risk for psychosis

Researchers led by Bradley S. Peterson, MD, director of the Institute for the Developing Mind at Children's Hospital Los Angeles, have shown that lower levels of conflict-related brain activity are associated with a higher risk for later psychosis.

23 Sep 2015

Researchers examine neuroanatomical signature of schizophrenia in different ethnic groups

While it is known that the incidence and outward symptoms of schizophrenia are strongly influenced by ethnic factors--for instance, patients from Asian ethnicities are more likely to experience visual hallucinations, whereas patients from western cultures and Caucasian ethnicities are more likely to suffer from auditory hallucinations--it was unclear if brain deficits would differ amongst suffers from various ethnic backgrounds.

14 Sep 2015

Psychosis, hepatitis C infection are greatest risk factors for mortality in marginalized Vancouver residents

Marginalized residents of Vancouver's Downtown Eastside are dying at more than eight times the national average, and treatable conditions are the greatest risk factors for mortality, researchers at the University of British Columbia have found.

11 Sep 2015

Special issue provides update on mental health diagnosis and treatment of older adults

The aging of the population, shifting diagnostic criteria, and new health care policy initiatives are some of the factors driving changes in mental health treatment for older Americans, according to the September special issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.

10 Sep 2015

Novel research tool identifies link between negative symptoms of schizophrenia and adverse clinical outcomes

A novel research tool developed by researchers from the Institute of Psychiatry, Psychology & Neuroscience at King's College London has identified a link between the negative symptoms experienced by people with schizophrenia and adverse clinical outcomes.

8 Sep 2015

Automated speech analysis program correctly identifies young people at risk for psychosis

An automated speech analysis program correctly differentiated between at-risk young people who developed psychosis over a two-and-a-half year period and those who did not. In a proof-of-principle study, researchers at Columbia University Medical Center, New York State Psychiatric Institute, and the IBM T. J. Watson Research Center found that the computerized analysis provided a more accurate classification than clinical ratings.

27 Aug 2015

Psychological disorders in COPD patients predict early hospital readmission

Researchers from The University of Texas Medical Branch at Galveston found that people with a psychological condition such as depression, anxiety, psychosis, or alcohol/drug abuse are more likely to be readmitted early into a hospital for complications of chronic obstructive pulmonary disease.

14 Aug 2015

Psychosis News and Research

Further Reading

New study reveals effect of cannabis potency on brain structure

UNC study reveals how specific schizophrenia symptoms linked to distinct brain circuits

Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

People with psychosis and addiction disorder may respond better to disorder-specific treatment

Team-based, coordinated specialty care approach produces better outcomes for people with first episode psychosis

Long-term lithium exposure does not increase renal dysfunction risk

New analysis finds illogical thoughts as most predictive of schizophrenia risk

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

Vraylar (cariprazine) capsules now approved by FDA to treat schizophrenia, bipolar disorder in adults

Brain & Behavior Research Foundation to honor nine scientists with Outstanding Achievement Prizes

Minor hallucinations may predate Parkinson motor symptoms

Study shows antipsychotic medication increases death risk in patients with Parkinson's disease psychosis

Mylan releases generic version of Invega in the U.S.

Reduced conflict-related brain activity linked to higher risk for psychosis

Researchers examine neuroanatomical signature of schizophrenia in different ethnic groups

Psychosis, hepatitis C infection are greatest risk factors for mortality in marginalized Vancouver residents

Special issue provides update on mental health diagnosis and treatment of older adults

Novel research tool identifies link between negative symptoms of schizophrenia and adverse clinical outcomes

Automated speech analysis program correctly identifies young people at risk for psychosis

Psychological disorders in COPD patients predict early hospital readmission

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News